Ravulizumab-CWVZ

Final results of CHAMPION-NMOSD Phase III trial long-term extension will show zero relapses in patients on Ultomiris through a median follow-up of 170.3 weeks Phase III data selected as one of ‘Best of ECTRIMS 2025’, reinforcing its significance in advancing therapeutic standards in NMOSD Alexion, AstraZeneca Rare Disease, will present four abstracts, including one oral presentation, from its leading rare neurology portfolio at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Congress in Barcelona, Spain, 24 to 26 September 2025. Presentations will highlight the final long-term analysis of the CHAMPION-NMOSD Phase III trial as well as real-world data further supporting the safety profiles and efficacy of Ultomiris (ravulizumab) and Soliris (eculizumab) in adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD). Christophe Hotermans, Head of Global Medical Affairs, Alexion, said: “At ECTRIMS, new long-term clinical and real-world evidence will reinforce the potential of Ultomiris to eliminate relapses in most patients and elevate the standard of care for people living with AQP4-Ab+ NMOSD. From the final results of the CHAMPION-NMOSD Phase III trial to global, real-world Ultomiris and Soliris data, these presentations highlight Alexion’s continued commitment to reducing the burden of this debilitating disease and our aspiration to revolutionise what living with NMOSD can look like.” Sean Pittock, MD, Mayo Clinic Glenn W. and Katherine K. Hasse Chair Neurology, Applebaum Family Professor of Neuroscience, Professor of Neurology, Co-Director of the Neuroimmunology Laboratory and principal investigator in the CHAMPION-NMOSD Phase III trial, said: “These long-term data from the CHAMPION-NMOSD Phase III trial show that patients treated with Ultomiris remained relapse-free for more than three years, a significant achievement in a disease where every relapse can lead to permanent disability. It’s an honour to have these findings recognised as part of the ‘Best of ECTRIMS 2025’, underscoring the potential impact of these results in improving outcomes for patients with NMOSD.” Completion of CHAMPION-NMOSD Phase III trial long-term extension shows maintained relapse prevention with Ultomiris An oral presentation of the final safety and efficacy results from the long-term extension (LTE) of the global CHAMPION-NMOSD Phase III trial will demonstrate zero adjudicated on-trial relapses (OTR) in adults with AQP4-Ab+ NMOSD treated with Ultomiris through the median follow-up of 170.3 weeks (relapse risk reduction: 98.9%, hazard ratio (95% CI), 91.8-100; P < 0.0001). As one of the longest studies conducted in NMOSD, these data will reinforce the long-term clinical benefit of C5 inhibition with Ultomiris. Additionally, most patients treated with Ultomiris were clinically stable (81%) or improved (13.8%), as measured by the Hauser Ambulation Index (HAI) score, and had no clinically important worsening (91.4%) of disability measured with the Expanded Disability Status Scale (EDSS). Further, the data will show that 63% (17/27) of patients taking immunosuppressive therapy (IST) at baseline reduced their dose or discontinued at least one treatment, indicating a potential for reduced use IST while being treated with Ultomiris long-term. The safety profile was consistent with prior study analyses. Robust real-world evidence builds on the established benefits of C5 inhibition in NMOSD A virtual poster presentation will feature real-world clinical findings from the global NMO SPOTLIGHT Registry, showing that Ultomiris and Soliris led to a reduction in relapses for people with AQP4-Ab+ NMOSD. Among 56 adults, the annualised relapse rate (ARR) fell from 0.50 [95% CI: 0.33-0.72] during the year prior to starting treatment with Ultomiris or Soliris to 0.02 [95% CI: 0.00-0.05] while on treatment, with no one experiencing more than one relapse. Among patients who switched from rituximab (n=15), no relapses were reported while treated with Ultomiris or Soliris, compared to an ARR of 0.47 [95% CI: 0.19-0.96] in the year prior to switching. These findings highlight the strong real-world clinical benefit of Ultomiris and Soliris in relapse prevention. A separate poster presentation will share interim analysis results from a real-world study from Japan evaluating Ultomiris in patients with AQP4-Ab+ NMOSD who had a suboptimal response to satralizumab. Among 11 patients receiving Ultomiris for at least six months (10.9±1.4 months on average), 10 remained relapse-free. In addition, use of concomitant immunosuppressive drugs was reduced in all patients. The switch to Ultomiris also showed positive changes in inflammatory biomarkers, as measured by changes in CD19+CD27-IgD- double negative B cells (%DNB) and unswitched memory B cells (%USM) at two months follow-up after treatment initiation. Lastly, a virtual poster presentation will share findings from the ongoing AMAZE study, a 78-week observational trial to evaluate the biological effects of Ultomiris, on clinical, serological and radiological measures of disease, and better understand the impact of social determinants of health on access to care and treatment outcomes for living with AQP4-Ab+ NMOSD. Upon study completion, these data may help guide clinicians towards optimised and equitable healthcare practices for people living with AQP4-Ab+ NMOSD. Lead Author Abstract Title Presentation Details Lead Author Pittock, SJ Abstract Title Long-term efficacy and safety of ravulizumab in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: final analysis of the phase 3 CHAMPION-NMOSD trial Presentation Details Oral Presentation Abstract ID: O109 26 September 2025 9:05 – 9:12 CEST Lead Author Sotirchos, ES Abstract Title Real-world clinical outcomes with eculizumab and ravulizumab in anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD): results from the global NMO SPOTLIGHT Registry Presentation Details ePoster Presentation Abstract ID: P1749 Lead Author Sato, W Abstract Title A real-world study of the effectiveness and safety of ravulizumab in AQP4+ NMOSD patients with suboptimal response to satralizumab in Japan - interim analysis- Presentation Details Poster Presentation Abstract ID: P867 Lead Author Okuda, D Abstract Title Clinical and Radiological Outcomes in People with Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Following Ravulizumab Treatment (AMAZE) Presentation Details ePoster Presentation Abstract ID: P1058 Notes Alexion Alexion, AstraZeneca Rare Disease, is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and delivery of life-changing medicines. A pioneering leader in rare disease for more than three decades, Alexion was the first to translate the complex biology of the complement system into transformative medicines, and today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US. AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here. tags Corporate and financial

9 月 17 日，阿斯利康宣布，Fasenra （本瑞利珠单抗）的 RESOLUTE III 期试验尽管显示出数值改善，但在慢性阻塞性肺病 (COPD) 患者的主要终点方面并未达到统计学意义。 截图来源：阿斯利康官网 RESOLUTE 是一项随机、双盲、安慰剂对照的 III 期试验，旨在评估本瑞利珠单抗 100 mg 对有频繁 COPD 发作史和血液嗜酸性粒细胞计数 (BEC) 升高 ≥ 300 个细胞/µL 的中度至极重度 COPD 患者的疗效和安全性。 本瑞利珠单抗在试验中的安全性和耐受性概况与该药物的已知概况一致。阿斯利康将分析 RESOLUTE 的完整数据集，以进一步了解结果，并将在未来与科学界分享。 本瑞利珠单抗是一款精准靶向嗜酸性粒细胞（EOS）的抗 IL-5R 创新生物制剂，此前已经获批嗜酸性粒细胞哮喘、变应性肉芽肿血管炎适应症。 自上市以来，本瑞利珠单抗的销售额连年上涨。 2024 年，该药的全球销售额达到16.89 亿美元，同比增长 8.76%。2025 上半年，本瑞利珠单抗卖了 9.2 亿美元，同比增长 18%。 截图来源：Insight 数据库 封面来源：企业logo 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。 编辑：ccai PR 稿对接：微信 insightxb 投稿：微信 insightxb；邮箱 insight@dxy.cn